Role and New Insights of Pirfenidone in Fibrotic Diseases

被引：132

作者：

Alejandro Lopez-de la Mora, David ^{[1
]}

Sanchez-Roque, Cibeles ^{[1
]}

Montoya-Buelna, Margarita ^{[1
]}

Sanchez-Enriquez, Sergio ^{[1
]}

Lucano-Landeros, Silvia ^{[1
]}

Macias-Barragan, Jose ^{[1
,2
]}

Armendariz-Borunda, Juan ^{[1
]}

机构：

[1] Univ Guadalajara, Dept Mol Biol & Genom, Inst Mol Biol & Gene Therapy, Guadalajara 44280, Jalisco, Mexico

[2] Univ Guadalajara, CUValles, Dept Ciencias Salud, Ameca 46600, Mexico

来源：

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES | 2015年 / 12卷 / 11期

关键词：

Pirfenidone; fibrosis; inflammation; idiopathic pulmonary fibrosis; IDIOPATHIC PULMONARY-FIBROSIS; LIVER FIBROSIS; PHARMACOKINETICS; EXPRESSION; THERAPIES; CYTOKINE; TIMP-1; SAFETY; TRIAL;

D O I：

10.7150/ijms.11579

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-beta 1, TNF-alpha, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries. Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.

引用

页码：840 / 847

页数：8

共 51 条

[1]

Where do we stand with IPF treatment? [J].